

Pfizer Pipeline | Key Anticipated 2026 Catalysts

Regulatory Decisions

HYMPAVZI (marstacimab)

Hemophilia A/B with Inhibitors (BASIS)

- **PADCEV (enfortumab vedotin)¹**
Cisplatin-ineligible Muscle-invasive Bladder Cancer (EV-303)

PADCEV (enfortumab vedotin)

Cisplatin-eligible Muscle-invasive Bladder Cancer (EV-304)

TUKYSA (tucatinib)

1L HER2+ Metastatic Breast Cancer Maintenance (HER2CLIMB-05)

- Approved
- Not approved

Data Readouts

ELREXFIO (elranatamab)

Double-class Exposed Relapsed / Refractory Multiple Myeloma (MagnetisMM-5)

LITFULO (ritlecitinib)

Vitiligo (TRANQUILLO)

Lyme Disease Vaccine Candidate (PF-07307405)

Lyme Disease Infection (VALOR)

Mevrometostat (PF-06821497)

1-2L Metastatic Castration-resistant Prostate Cancer Post-abiraterone (MEVPRO-1)

Sigvotatug vedotin (PF-08046047)

2L+ Non-squamous Metastatic Non-small Cell Lung Cancer (Be6A LUNG-01)

TALZENNA (talazoparib) + XTANDI (enzalutamide)

1L HRRm Metastatic Castration-sensitive Prostate Cancer (TALAPRO-3)

Ultra-Long-Acting GLP-1 (PF'3944 / MET-097i)

Monthly Chronic Weight Management (VESPER-3) | Phase 2b

Ultra-Long-Acting GLP-1 + Amylin (PF'3945 / MET-233i) Combo

Chronic Weight Management | Phase 1/2

- Completed
- No longer anticipated in 2026

Pivotal Study Starts

HYMPAVZI (marstacimab)

Moderate Hemophilia A/B

LITFULO (ritlecitinib)

Moderate Alopecia Areata

NURTEC (rimegepant)

Chronic Migraine

NURTEC (rimegepant)

Redosing (Acute Treatment of Migraine)

PADCEV (enfortumab vedotin)

Muscle-invasive Bladder Cancer (Bladder Sparing)

PCV25 (PF-07872412)

Pneumococcal Infection

● PD-1xVEGF (PF'4404)¹

1L Metastatic Colorectal Cancer (Symbiotic-GI-03)

PD-1xVEGF (PF'4404)

1L Endometrial Cancer

PD-1xVEGF (PF'4404)

1L Squamous / Non-squamous Non-small Cell Lung Cancer

PD-1xVEGF (PF'4404) + PADCEV (enfortumab vedotin)

1L Metastatic Urothelial Cancer

Sigvotatug vedotin (PF-08046047)

1L Non-small Cell Lung Cancer TPS All Comers

Ultra-Long-Acting GLP-1 (PF'3944 / MET-097i)*

10 Studies

- Study started
- Study discontinued / start no longer anticipated in 2026

1. Achieved in late 2025; 1L=First-line; 1-2L=First- or second-line; 2L+=Second-line plus; HRRm=Homologous recombination repair mutant; TPS=Tumor proportion score

*Includes VESPER-4 study of ultra-long-acting GLP-1 for weekly chronic weight management in participants with obesity or overweight and without Type 2 diabetes mellitus (achieved first subject first dose in late 2025), VESPER-5 study of ultra-long-acting GLP-1 for weekly chronic weight management in participants with obesity or overweight and Type 2 diabetes mellitus, VESPER-6 study of ultra-long-acting GLP-1 for monthly chronic weight management, and seven additional studies of MET-097i.

This list is not inclusive of all ongoing programs in Pfizer's product pipeline and inclusion in this list does not guarantee continued investment. Catalyst descriptions are intended to be high-level and may present disease area rather than indication. Data readout completion does not imply that any or all endpoints of the study were met. Data readouts are Phase 3 unless otherwise noted. Listed pivotal studies may include those that are Phase 3, Phase 4, or potentially registration-enabling Phase 2 or 2/3 studies. Some pivotal study starts, which are defined by first subject first dose (FSFD), may be subject, among other things, to data generation in earlier-stage studies and/or alignment with regulatory agencies. Many clinical research studies are event driven and readouts are therefore subject to change. Pfizer assumes no obligation to update this information in response to new or future developments. Please see Pfizer's SEC filings, press releases and other disclosures for additional information.